Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.46 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4585179 | 1.00 | EPHX1 (0.56) | EPHX1SMN1; SMN2EPHX2ASAH2FNTA | |
| SCHEMBL4585800 | 1.00 | EPHX1 (0.56) | EPHX1SMN1; SMN2EPHX2ASAH2FNTA | |
| SCHEMBL4586041 | 0.85 | EPHX1 (0.63) | EPHX1SMN1; SMN2FNTAFNTBFAAH | |
| SCHEMBL4585957 | 0.85 | EPHX1 (0.63) | EPHX1SMN1; SMN2FNTAFNTBFAAH | |
| SCHEMBL14064432 | 0.85 | EPHX1 (0.63) | EPHX1SMN1; SMN2FNTAFNTBFAAH | |
| SCHEMBL21724268 | 0.85 | EPHX1 (0.52) | EPHX1SMN1; SMN2EPHX2 | |
| SCHEMBL21724650 | 0.85 | EPHX1 (0.52) | EPHX1SMN1; SMN2EPHX2 | |
| SCHEMBL21724271 | 0.85 | EPHX1 (0.52) | EPHX1SMN1; SMN2EPHX2 | |
| SCHEMBL21724646 | 0.85 | EPHX1 (0.52) | EPHX1SMN1; SMN2EPHX2 | |
| SCHEMBL7769494 | 0.85 | EPHX1 (0.71) | EPHX1SMN1; SMN2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507562-B2 | Synthesis of (1)-beta-elemene, (-)-beta-elemenal, (-)-beta-elemenol, (-)-beta-elemene fluoride and their analogues, intermediates, and composition and uses thereof | HYWE PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| WO-2008113992-A2 | GEL COMPOSITIONS COMPRISING UREA DERIVATIVES | PLIVA HRVATSKA D.O.O. (HR) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008113992-A2 | GEL COMPOSITIONS COMPRISING UREA DERIVATIVES | PLIVA HRVATSKA D.O.O. (HR) | 2008-09-25 | — | — | WO | disclosed |
| EP-1773741-A4 | SYNTHESIS OF (-)-BETA-ELEMENE, (-)-BETA-ELEMENAL, (-)-BETA-ELEMENOL, (-)-BETA-ELEMENE FLUORIDE AND THEIR ANALOGUES, INTERMEDIATES AND COMPOSITION AND USES THEREOF | LONG RANGE INTERNAT USA LTD IN (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20070135526-A1 | Synthesis of (1)-beta-elemene, (-)-beta-elemenal, (-)-beta-elemenol, (-)-beta-elemene fluoride and their analogues, intermediates, and composition and uses thereof | LONG RANGE INTERNATIONAL USA LIMITED, INC. | 2007-06-14 | — | — | US | disclosed |
| EP-1773741-A2 | SYNTHESIS OF (-)-BETA-ELEMENE, (-)-BETA-ELEMENAL, (-)-BETA-ELEMENOL, (-)-BETA-ELEMENE FLUORIDE AND THEIR ANALOGUES, INTERMEDIATES AND COMPOSITION AND USES THEREOF | Long Range International USA Limited, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006016912-A2 | SYNTHESIS OF (-)-BETA-ELEMENE, (-)-BETA-ELEMENAL, (-)-BETA-ELEMENOL, (-)-BETA-ELEMENE FLUORIDE AND THEIR ANALOGUES, INTERMEDIATES AND COMPOSITION AND USES THEREOF | LONG RANGE INTERNATIONAL USA LIMITED, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20040142976-A1 | Pyridylfuran and pyridylthiophene compounds | PFIZER INC. | 2004-07-22 | — | — | US | disclosed |
| US-6696470-B2 | FOR THERAPY OF ARTHRITIS, ASTHMA, BONE RESORPTION DISEASE, CACHEXIA, CARDIOVASCULAR DISEASE, CEREBRAL MALARIA, CROHN'S DISEASE, DIABETES, FEVER OR MYALGIA DUE TO INFECTION, GOUT, GRAFT VERSUS HOST REACTION, INFLAMMATION OF ORGANS, ETC. | PFIZER INC. | 2004-02-24 | — | — | US | disclosed |
| US-20020022729-A1 | Pyridylfuran and pyridylthiophene compounds | KAWAI AKIYOSHI (JP) | 2002-02-21 | — | — | US | disclosed |
| EP-0853083-B1 | Pyridylfuran and pyridylthiophene compounds and pharmaceutical use thereof | PFIZER (US) | 2001-09-12 | — | — | EP | disclosed |
| US-6048880-A | THERAPY FOR CYTOKINE SENSITIVE DISEASES | PFIZER PHARAMACEUTICALS INC. (JP) | 2000-04-11 | — | — | US | disclosed |
| EP-0853083-A1 | Pyridylfuran and pyridylthiophene compounds and pharmaceutical use thereof | PFIZER INC. (US) | 1998-07-15 | — | — | EP | disclosed |
| EP-0652749-A4 | METHODS AND COMPOSITIONS FOR INHIBITING 5-g(a)-REDUCTASE ACTIVITY. | ARCH DEV CORP (US) | 1997-04-09 | — | — | EP | disclosed |
| EP-0652749-A1 | METHODS AND COMPOSITIONS FOR INHIBITING 5$g(a)-REDUCTASE ACTIVITY | ARCH DEVELOPMENT CORPORATION (US) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994001100-A1 | METHODS AND COMPOSITIONS FOR INHIBITING 5α-REDUCTASE ACTIVITY | ARCH DEVELOPMENT CORPORATION (US) | 1994-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142976-A1 | Pyridylfuran and pyridylthiophene compounds | MC2R, FCGR2A, OGFR | EPHX1 1266/4885SMN1; SMN2 3438/4885EPHX2 867/4885 |
| US-20020022729-A1 | Pyridylfuran and pyridylthiophene compounds | MC2R, CRHR1, NR3C2 | EPHX1 1227/4885SMN1; SMN2 3340/4885EPHX2 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.